Limits...
Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.

Xue R, Yang C, Zhao F, Li D - Onco Targets Ther (2014)

Bottom Line: CDH13 hypermethylation was also associated with pathological types.Interestingly, CDH13 mRNA overexpression was found to correlate with better overall survival only in adenocarcinoma patients (hazard ratio, 0.42; P=9.6e-09), not in squamous cell carcinoma patients (hazard ratio, 0.93; P=0.59).CDH13 hypermethylation and mRNA expression play an important role in carcinogenesis, progression, and development, as well as clinical outcomes.

View Article: PubMed Central - PubMed

Affiliation: Global Health Institute, School of Public Health, Wuhan University, Wuhan, People's Republic of China.

ABSTRACT
Aberrant methylation of CpG dinucleotides is a commonly observed epigenetic modification in human cancer. Thus, detection of aberrant gene promoter methylation as a tool for diagnosis of tumors or as a prognostic marker has been widely described for many types of cancers, including nonsmall cell lung cancer (NSCLC). Emerging evidence indicates that CDH13 is a candidate tumor suppressor in several types of human tumors, including NSCLC. However, the correlation between CDH13 hypermethylation and clinicopathological characteristics of NSCLC remains unclear. In the current study, we conducted a systematic review and meta-analysis to quantitatively evaluate the effects of CDH13 hypermethylation on the incidence of NSCLC and clinicopathological characteristics. Final analysis of 803 NSCLC patients from eleven eligible studies was performed. CDH13 hypermethylation was observed to be significantly higher in NSCLC than in normal lung tissue, with the pooled odds ratio (OR) from seven studies including 448 NSCLC and 345 normal lung tissue (OR, 7.85; 95% confidence interval, 5.12-12.03; P<0.00001). CDH13 hypermethylation was also associated with pathological types. The pooled OR was obtained from four studies, including 111 squamous cell carcinoma and 106 adenocarcinoma (OR, 0.35; 95% confidence interval, 0.19-0.66; P=0.001), which indicated that CDH13 hypermethylation plays a more important role in the pathogenesis of adenocarcinoma. NSCLC with CDH13 hypermethylation was found more frequently in poorly differentiated NSCLC patients. NSCLC patients with CDH13 hypermethylation had a lower survival rate than those without CDH13 hypermethylation. In addition, CDH13 mRNA high expression was found to correlate with better overall survival for all NSCLC patients followed for 20 years (hazard ratio, 0.81; P=0.0056). Interestingly, CDH13 mRNA overexpression was found to correlate with better overall survival only in adenocarcinoma patients (hazard ratio, 0.42; P=9.6e-09), not in squamous cell carcinoma patients (hazard ratio, 0.93; P=0.59). The results of this meta-analysis suggest that CDH13 hypermethylation is associated with an increased risk and worse survival in NSCLC. CDH13 hypermethylation and mRNA expression play an important role in carcinogenesis, progression, and development, as well as clinical outcomes.

No MeSH data available.


Related in: MedlinePlus

The clinical relevance of CDH13 was corroborated in a patient survival analysis using an online database containing the expression of 22,277 genes and 20-year survival information of 1,405 patients.Notes:CDH13 mRNA high expression was found to correlate with better overall survival for all nonsmall cell lung cancer patients followed for 20 years. (A) HR, 0.81; P=0.0056. In addition, CDH13 mRNA high expression was found to correlate with better overall survival only in adenocarcinoma patients. (B) HR, 0.42; P=9.6e–09, but not patients with squamous cell carcinoma. (C) HR, 0.93; P=0.59.Abbreviation: HR, hazard ratio.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4222896&req=5

f8-ott-7-1987: The clinical relevance of CDH13 was corroborated in a patient survival analysis using an online database containing the expression of 22,277 genes and 20-year survival information of 1,405 patients.Notes:CDH13 mRNA high expression was found to correlate with better overall survival for all nonsmall cell lung cancer patients followed for 20 years. (A) HR, 0.81; P=0.0056. In addition, CDH13 mRNA high expression was found to correlate with better overall survival only in adenocarcinoma patients. (B) HR, 0.42; P=9.6e–09, but not patients with squamous cell carcinoma. (C) HR, 0.93; P=0.59.Abbreviation: HR, hazard ratio.

Mentions: The clinical relevance of CDH13 was further corroborated in a patient survival analysis, using an online database containing the expression of 22,277 genes and 20-year survival information of 1,809 patients.30 The database has recently been updated to include survival information of 1,405 NSCLC patients (http://www.kmplot.com/analysis/). CDH13 mRNA high expression was found to correlate with better OS for all NSCLC patients followed for 20 years (Figure 8A; HR, 0.81; P=0.0056). In addition, CDH13 mRNA high expression was found to correlate with better relapse OS only in adenocarcinoma patients (Figure 8B; HR, 0.42; P=9.6e–09), but not squamous cell carcinoma patients (Figure 8C; HR, 0.93; P=0.59).


Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.

Xue R, Yang C, Zhao F, Li D - Onco Targets Ther (2014)

The clinical relevance of CDH13 was corroborated in a patient survival analysis using an online database containing the expression of 22,277 genes and 20-year survival information of 1,405 patients.Notes:CDH13 mRNA high expression was found to correlate with better overall survival for all nonsmall cell lung cancer patients followed for 20 years. (A) HR, 0.81; P=0.0056. In addition, CDH13 mRNA high expression was found to correlate with better overall survival only in adenocarcinoma patients. (B) HR, 0.42; P=9.6e–09, but not patients with squamous cell carcinoma. (C) HR, 0.93; P=0.59.Abbreviation: HR, hazard ratio.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4222896&req=5

f8-ott-7-1987: The clinical relevance of CDH13 was corroborated in a patient survival analysis using an online database containing the expression of 22,277 genes and 20-year survival information of 1,405 patients.Notes:CDH13 mRNA high expression was found to correlate with better overall survival for all nonsmall cell lung cancer patients followed for 20 years. (A) HR, 0.81; P=0.0056. In addition, CDH13 mRNA high expression was found to correlate with better overall survival only in adenocarcinoma patients. (B) HR, 0.42; P=9.6e–09, but not patients with squamous cell carcinoma. (C) HR, 0.93; P=0.59.Abbreviation: HR, hazard ratio.
Mentions: The clinical relevance of CDH13 was further corroborated in a patient survival analysis, using an online database containing the expression of 22,277 genes and 20-year survival information of 1,809 patients.30 The database has recently been updated to include survival information of 1,405 NSCLC patients (http://www.kmplot.com/analysis/). CDH13 mRNA high expression was found to correlate with better OS for all NSCLC patients followed for 20 years (Figure 8A; HR, 0.81; P=0.0056). In addition, CDH13 mRNA high expression was found to correlate with better relapse OS only in adenocarcinoma patients (Figure 8B; HR, 0.42; P=9.6e–09), but not squamous cell carcinoma patients (Figure 8C; HR, 0.93; P=0.59).

Bottom Line: CDH13 hypermethylation was also associated with pathological types.Interestingly, CDH13 mRNA overexpression was found to correlate with better overall survival only in adenocarcinoma patients (hazard ratio, 0.42; P=9.6e-09), not in squamous cell carcinoma patients (hazard ratio, 0.93; P=0.59).CDH13 hypermethylation and mRNA expression play an important role in carcinogenesis, progression, and development, as well as clinical outcomes.

View Article: PubMed Central - PubMed

Affiliation: Global Health Institute, School of Public Health, Wuhan University, Wuhan, People's Republic of China.

ABSTRACT
Aberrant methylation of CpG dinucleotides is a commonly observed epigenetic modification in human cancer. Thus, detection of aberrant gene promoter methylation as a tool for diagnosis of tumors or as a prognostic marker has been widely described for many types of cancers, including nonsmall cell lung cancer (NSCLC). Emerging evidence indicates that CDH13 is a candidate tumor suppressor in several types of human tumors, including NSCLC. However, the correlation between CDH13 hypermethylation and clinicopathological characteristics of NSCLC remains unclear. In the current study, we conducted a systematic review and meta-analysis to quantitatively evaluate the effects of CDH13 hypermethylation on the incidence of NSCLC and clinicopathological characteristics. Final analysis of 803 NSCLC patients from eleven eligible studies was performed. CDH13 hypermethylation was observed to be significantly higher in NSCLC than in normal lung tissue, with the pooled odds ratio (OR) from seven studies including 448 NSCLC and 345 normal lung tissue (OR, 7.85; 95% confidence interval, 5.12-12.03; P<0.00001). CDH13 hypermethylation was also associated with pathological types. The pooled OR was obtained from four studies, including 111 squamous cell carcinoma and 106 adenocarcinoma (OR, 0.35; 95% confidence interval, 0.19-0.66; P=0.001), which indicated that CDH13 hypermethylation plays a more important role in the pathogenesis of adenocarcinoma. NSCLC with CDH13 hypermethylation was found more frequently in poorly differentiated NSCLC patients. NSCLC patients with CDH13 hypermethylation had a lower survival rate than those without CDH13 hypermethylation. In addition, CDH13 mRNA high expression was found to correlate with better overall survival for all NSCLC patients followed for 20 years (hazard ratio, 0.81; P=0.0056). Interestingly, CDH13 mRNA overexpression was found to correlate with better overall survival only in adenocarcinoma patients (hazard ratio, 0.42; P=9.6e-09), not in squamous cell carcinoma patients (hazard ratio, 0.93; P=0.59). The results of this meta-analysis suggest that CDH13 hypermethylation is associated with an increased risk and worse survival in NSCLC. CDH13 hypermethylation and mRNA expression play an important role in carcinogenesis, progression, and development, as well as clinical outcomes.

No MeSH data available.


Related in: MedlinePlus